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The absence of detectable ADAMTS-4 (aggrecanase-1) activity in synovial fluid is 1 
a predictive indicator of autologous chondrocyte implantation success. 2 
3 
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Abstract 4 
Background: Autologous chondrocyte implantation (ACI) is used worldwide in the 5 
treatment of cartilage defects in the knee. Several demographic and injury specific risk 6 
factors have been identified that can affect the success of ACI treatment. However, the 7 
discovery of predictive biomarkers in this field has thus far been overlooked.  8 
Hypothesis/Purpose: The purpose of this study was to identify potential biomarkers in 9 
synovial fluid (SF) and plasma that can be used in the pre-operative setting to help 10 
optimise patient selection for cell-based cartilage repair strategies. 11 
Study design: Case series; Level of evidence, 4. 12 
Methods: Fifty four ACI-treated patients were included. Cartilage oligomeric matrix 13 
protein (COMP), hyaluronan, soluble CD14 levels and ADAMTS-4 activity in synovial 14 
fluid and COMP and hyaluronan in plasma were measured. Baseline and post-15 
operative functional outcome was determined using the patient-reported Lysholm 16 
score. To find predictors of post-operative function, linear and logistic regression 17 
analyses were performed. The dependent variables were baseline and post-operative 18 
Lysholm score, the independent variables were patient age and body mass index, 19 
defect location, defect area, having a bone-on-bone defect, type of defect patch type 20 
(periosteum or collagen), requirement of an extra procedure and baseline biomarker 21 
levels.  22 
Results Mean baseline Lysholm score was 47.4(+/-17.0), which improved to 64.6(+/-23 
21.7) post-operatively. The activity of ADAMTS-4 in synovial fluid was identified as an 24 
independent predictor of post-operative Lysholm score. Indeed, simply the presence or 25 
absence of ADAMTS-4 activity in synovial fluid appeared to be the important predictive 26 
factor (determined by contingency analysis). Other predictive factors were baseline 27 
Lysholm score, age at ACI and the defect patch type used. 28 
Conclusions The absence of ADAMTS-4 activity in the synovial fluid of joints with 29 
cartilage defects may be used in conjunction with known demographic risk factors in 30 
the development of an ACI treatment algorithm to help inform the preclinical decision.  31 
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What is known about the subject: There are no known predictive biomarkers for ACI. 32 
What this study adds to existing knowledge: This study has identified the first 33 
biological predictor for ACI, which could be used in deciding the best treatment. 34 
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Introduction 35 
 A recent white paper on how to move forward with cell-based advanced therapies has 36 
highlighted the need for improved predictive preclinical efficacy testing within Europe15. 37 
Hence, the refinement and optimisation of cell therapy protocols for increased efficacy 38 
in the treatment of early osteoarthritis (OA) is more relevant than ever before. Some 39 
patient demographics have been linked to failure, including age, gender, body mass 40 
index (BMI) and the size of cartilage lesion19,20,41 and are used when deciding on ACI 41 
treatment. Currently there are no wet biomarker tests available to clinicians that can 42 
accurately and reproducibly predict the outcome of cell therapies for cartilage repair. 43 
There is, therefore, a clinical and financial need for reproducible pre-operative 44 
biomarkers assays, to be used in conjunction with known demographic risk factors, to 45 
help the clinician decide if a patient should be considered suitable for treatment using 46 
these interventions.  47 
Wet biomarkers derived from body fluids (e.g. synovial fluid and blood plasma) 48 
represent an attractive option for the pre-operative screening of patients. In addition, 49 
such markers could also enable longitudinal analyses to monitor treatment outcome or 50 
act as surrogate outcomes, or help to elucidate the reasons why some patients benefit 51 
from treatments when others fail to do so. Finally, the characterisation of specific 52 
biochemical and or cellular changes in these fluids, associated with treatment failure or 53 
success, may help to identify markers to target and improve the therapeutic effect16.  54 
Several compounds found in the blood and synovial fluid have been associated 55 
with cartilage injury and OA progression, including matrix molecules and enzymes 56 
associated with cartilage degradation such as hyaluronan (HA)36, cartilage oligomeric 57 
matrix protein (COMP)7, chondroitin sulphate (CS)3, aggrecanase-1/aggrecanase-2 58 
(ADAMTS-4/ADAMTS-5)18,23,46 and matrix metalloproteinases (MMPs)1. In addition, 59 
other molecules may be suitable as biomarkers such as those associated with 60 
inflammation, including soluble CD14 (sCD14)11,26. The main objective of this study 61 
was to begin the process of establishing a reliable panel of biochemical markers that 62 
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could be used in the pre-operative setting, to optimise treatment selection for cartilage 63 
defects. 64 
65 
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Materials and Methods 66 
Patients 67 
Following approval from the Black Country National Research Ethics Service (NRES) 68 
committee (06/Q2601/9) and with informed consent, synovial fluid and plasma was 69 
obtained pre-cell implantation from all consented patients treated with autologous 70 
chondrocyte implantation (ACI) at our centre from 2007 to 2012 inclusive. ACI is a two-71 
stage procedure, with stage I an arthroscopic cartilage harvest and cells being 72 
implanted during an arthrotomy at stage II. The procedure was performed using 73 
culture-expanded chondrocytes, as described previously4,6,32. The indication for ACI in 74 
all of the patients included in this study was the presence of a focal cartilage defect in 75 
the knee. All patients included in the study had received either debridement or 76 
microfracture as a previous surgical treatment for these defects and as such none of 77 
the patients could be described as acutely injured. At baseline (pre-ACI), we recorded 78 
age, gender, BMI and the functional status as characterised by the modified Lysholm 79 
scale (score range is 0-100, where the maximum score is 100, which denotes an 80 
‘excellent’ functioning knee joint)38. We further recorded the defect location and size, 81 
whether the defect was ‘bone on bone’ and whether the patient underwent additional 82 
procedures including ligament reconstruction, meniscal replacement surgery or 83 
osteotomy. We also recorded the type of material used to cover the defect before cell 84 
implantation i.e. autologous periosteum or porcine collagen membrane (Chondro-85 
Gide®; Geistlich Ltd, Manchester, UK). A patient was described as a ‘responder’ or a 86 
‘non-responder’ based on the change in 1-year post-operative Lysholm score. 87 
Responders were patients who had improved by at least 10 points, which is 88 
comparable to the published minimum clinically important difference for 100 point 89 
functional knee scores reported in other studies14,34,37. 90 
Synovial fluid and plasma collection and storage 91 
To collect synovial fluid, patients’ knee joints were injected with 20mls of saline 92 
followed by 20 cycles of extension and flexion prior to intra-articular aspiration. We 93 
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have been collecting synovial fluid from knee joints for biomarker analyses for the last 94 
15 years. This process of collection has been optimised for ease of synovial fluid 95 
volume retrieval by the clinician and to ensure, as much as possible, consistency 96 
between samples. Blood plasma was obtained by venepuncture at the time of ACI. 97 
Synovial fluid and blood were centrifuged at 600g for 15 minutes at 40C. The synovial 98 
fluid and blood plasma were then divided into aliquots and stored in liquid nitrogen prior 99 
to biomarker analyses. The dilution of synovial fluids was accounted for by normalising 100 
synovial fluid biomarker values to the urea concentration in blood plasma. In brief, urea 101 
concentrations were measured in the synovial fluid and in the blood plasma (which 102 
were harvested at the same time) and a dilution factor was calculated for the synovial 103 
fluid based on the assumption that the urea concentration is equivalent in plasma and 104 
synovial fluid, a previously reported methodology21. COMP, HA, sCD14 levels and 105 
ADAMTS-4 activity in synovial fluids were calculated by multiplying assay derived 106 
concentrations by the dilution factors obtained from the urea analyses. 107 
COMP and HA quantification in synovial fluid and matched blood plasma 108 
COMP levels in synovial fluid and plasma were determined using an enzyme-linked 109 
immunosorbant assay (ELISA) (BioVendor Laboratory Medicine, Modrice, Czech 110 
Republic). For calculations of COMP concentration, the logit log function was used to 111 
linearise standard curves. HA levels in synovial fluid and plasma were measured using 112 
an enzyme-linked protein binding assay (Corgenix, Broomfield, CO). Third-order 113 
polynomial regression was used to generate the best-fit curve to calculate the 114 
concentration of HA in patient samples. For COMP and HA assays all commercially 115 
provided quality controls were within accepted limits. The limit of detection (LoD) for 116 
COMP and HA were calculated to be 0.1ng/ml and 17.8ng/ml respectively. The inter- 117 
and intra-assay co-efficient of variance was 7.1% and 1.6% for COMP assays and 118 
19.1% and 4.5% for HA assays, respectively. 119 
sCD14 quantification in synovial fluid  120 
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sCD14 was measured in synovial fluid samples using the Human sCD14 Quantikine® 121 
ELISA (R&D Systems, Minneapolis, MN). For calculations of sCD14 concentration the 122 
logit log function was used to linearise standard curves. The LoD was calculated to be 123 
141pg/ml. The inter- and intra-assay co-efficient of variance was 9.0% and 4.3%, 124 
respectively. 125 
ADAMTS-4 activity quantification in synovial fluid 126 
An end-point fluorometric substrate assay (SensoLyte®520 Aggrecanase-1 Assay Kit, 127 
AnaSpec, Fremont, CA) was used to measure ADAMTS-4 activity in synovial fluid 128 
samples. The kit contains an internally quenched 5-carboxyl fluorescein (FAM)/ 129 
tetramethylrhodamine (TAMRA) fluorescence resonance energy transfer (FRET) 130 
substrate which is optimised to specifically detect ADAMTS-4 activity (down to 4ng/ml). 131 
For calculations of ADAMTS-4 activity linear standard curves were constructed by 132 
plotting relative fluorescent units (RFU) versus the concentration of ADAMTS-4 133 
standards (AnaSpec). The LoD was calculated to be 1.4ng/ml, with inter- and intra-134 
assay co-efficient of variances being 12.3% and 1.7%, respectively. 135 
Statistical analysis 136 
The distributions of all continuous variables were investigated using quantile-quantile 137 
(QQ) plots. These showed that age, BMI and the Lysholm scores followed a normal 138 
distribution, whereas defect area and the levels of all biomarkers followed a log-normal 139 
distribution.  140 
Some biomarker levels were below the assay detection limit (‘non-detects’ or 141 
‘censoring’), in those cases, imputed biomarker levels were used that minimised bias29. 142 
The imputation was based on a larger set of biomarker samples, comprising all 143 
samples from the current study augmented with 66 samples from 53 patients collected 144 
at least 1 year post-operatively. When fewer than 10% of the specimens were a non-145 
detect for a specific biomarker, an imputation value of (1/√2) times the LoD was used. 146 
At non-detect levels above 10%, we imputed using the expected value of the biomarker 147 
level. These values were calculated using a censored log-normal distribution through 148 
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all biomarker levels above the detection limit28. However, no imputation was needed for 149 
such a biomarker when it was the dependent variable in the analysis; instead we used 150 
a censored regression analysis12. For patients with two baseline specimens i.e. a Stage 151 
I and a matched Stage II sample, the mean biomarker level both was used. 152 
To find predictors of post-operative functional status, a univariable linear 153 
regression analysis was performed using the post-operative Lysholm score as the 154 
dependent variable and including the baseline Lysholm score as a covariate. 155 
Independent variables were patient age at the time of ACI, BMI, defect location, defect 156 
area, having a bone-on-bone defect, type of defect patch type (periosteum or collagen), 157 
requirement of an extra procedure and the baseline level of the five synovial fluid 158 
biomarkers (HA, ADAMTS-4, COMP and sCD14) and the two plasma biomarkers (HA 159 
and COMP). A multivariable linear regression analysis was then performed based on 160 
all predictors with a univariable p-value below 0.15. Further univariable and 161 
multivariable linear regression analyses were performed to identify predictors of ACI 162 
outcome based on the responder definition described above, namely assuming that 163 
responders were patients with an improvement of at least 10 points14,34,37. These 164 
analyses were performed as logistic regression analyses, following the same 165 
methodology as outlined above for the linear regression analyses. The resulting model 166 
was then internally validated (see Appendix). 167 
For those biomarkers that were identified as having a predictive value we also 168 
plotted their baseline levels versus the difference from baseline Lysholm score in order 169 
to determine whether merely the presence of the biomarker or the quantity measured is 170 
important for predicting response. This was examined further in a 2-way contingency 171 
table analysis (Fisher’s exact test). Finally, for all biomarkers with a p-value in the 172 
multivariable linear or logistic regression analysis below 0.15, further linear regression 173 
analyses were performed to determine predictors of the biomarker levels amongst the 174 
other variables examined, i.e. all demographic and defect characteristics as well as the 175 
levels of the other biomarkers in the same fluid compartment (synovial fluid or plasma). 176 
  
10 
 
All regression analyses were performed using R vs 3.0.3 (R Foundation for Statistical 177 
Computing, Vienna, Austria), using the packages ‘envStats’, ‘distrEx’, ‘rms’ and ‘lme4’. 178 
All analyses used the appropriate transformation identified from the QQ plots, and a p-179 
value below 0.05 was assumed to denote statistical significance.180 
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Results 181 
Patients 182 
Fifty four patients undergoing ACI were included in this study with a mean baseline 183 
clinical Lysholm score of 47.4(+/-17.0) which improved to 64.6(+/-21.7) at post-184 
operative assessment (2.2+/-3.0 years post-treatment). Seventy seven percent of 185 
patients showed an increase in Lysholm score at this time point, with 59% improving at 186 
least 10 points, these were classed as responders in subsequent analyses. The study 187 
comprised samples from 38 male and 16 female patients, aged between 17 and 61 188 
years at the time of ACI. An overview of the demographic variables and defect 189 
characteristics analysed are detailed in Table 1. 190 
191 
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Table 1: Overview of demographic and defect variables. 192 
Variable Mean (SD),  
Median (IQR)  
or n (%) 
Range Number of  
non-detects (%) 
Age (years) 35.0 (10.2) 17-61  
Gender 
   Female 
   Male 
 
16 (30%) 
38 (70%) 
  
BMI 27.4 (4.1) 20-37  
Defect location 
   Medial femoral condyle 
   Lateral femoral condyle 
   Patella 
   Trochlea 
   Trochlea & patella 
   Tibial plateau 
 
35 (65%) 
5 (9%) 
5 (9%) 
5 (9%) 
1 (2%) 
3 (6%) 
  
Defect area (cm2) 3.6 (1.5-6.0) 0.02-43.2  
Bone-on-bone 
   No 
   Yes 
 
41 (95%) 
2 (5%) 
  
Patch type 
   Collagen 
   Periosteum 
 
47 (87%) 
7 (13%) 
  
Additional procedure 
   No 
   Yes 
 
32 (59%) 
22 (41%) 
  
Pre-op Lysholm 47.4 (17.0) 13-92  
Post-op Lysholm 64.6 (21.7) 29-100  
Synovial fluid markers 
   HA (mg/ml; ×106) 
   ADAMTS-4 (ng/ml) 
   COMP (µg/ml; ×104) 
   sCD14 (ng/ml; ×102) 
 
1.7 (1.1-3.1) 
0.40 (0.40-41.5) 
9.3 (4.0-16.1) 
8.8 (6.5-12.9) 
 
0.4-9.1 
0.40-416 
0.03-42.6 
0.31-29.5 
 
0 (0%) 
54 (71%) 
0 (0%) 
1 (1%) 
Plasma markers 
   HA (ng/ml) 
   COMP (ng/ml; ×102) 
 
17.4 (7.3-28.0) 
7.0 (4.8-13.3) 
 
0.0-79.3 
1.0-27.5 
 
0 (0%) 
0 (0%) 
SD is Standard Deviation; IQR is Interquartile Range (lower to upper quartile). The 193 
values for non-detects were imputed when calculating median biomarker levels. 194 
 195 
Biomarker levels 196 
From the 54 patients included, 76 fluid samples were collected: 47 at stage I (pre-197 
cartilage harvest) and 29 at stage II (pre-cell implantation, 3-4 weeks later). In 11 198 
patients a sample was collected at both stages. The mean synovial fluid dilution factor 199 
(calculated using blood plasma urea content)21 was 4.7+/-3.6 and in the responder and 200 
non-responder groups the dilution factor was 4.4+/-3.1 and 4.9+/-3.7, respectively. For 201 
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two biomarkers (sCD14 and ADAMTS-4), we found samples with undetectable levels. 202 
In order to use the biomarker variables with these ‘non-detects’ as predictors in a 203 
regression analysis, imputed values were used for all non-detect cases. For sCD14 204 
levels, where sCD14 was below the detection limit in only one sample, the imputed 205 
value was taken equal to (1/√2) times the LoD of 0.14ng/ml (0.10ng/ml). The ADAMTS-206 
4 determinations had 71% of non-detects and its lower detection limit (LDL) was 207 
3.7ng/ml. A censored log-normal distribution was fitted to the ADAMTS-4 data, giving a 208 
mean of -1.6 and an SD of 4.4. The expected value of ADAMTS-4 under the above log-209 
normal distribution and the condition that the value was below 3.7ng/ml was 0.40ng/ml. 210 
This value of 0.40 was used to impute the non-detect cases. Mean baseline biomarker 211 
levels after imputation are summarised in Table 1.  212 
Regression analyses of predictors of post-operative Lysholm score following ACI 213 
treatment. 214 
When using post-operative Lysholm as the main outcome, and including baseline 215 
Lysholm as a covariate, univariable linear regression models found two variables 216 
potentially associated with better outcome, namely lower age and lower ADAMTS-4 217 
activity (Table 2A). A higher baseline Lysholm, lower age and lower ADAMTS-4 activity 218 
all proved to be significantly associated with a higher 1-year Lysholm score in a 219 
multivariable regression analysis (Table 2B).  220 
221 
  
14 
 
Table 2A: Univariable linear regression analysis of predictors of post-op Lysholm 222 
score. 223 
 224 
Variable Regression coefficient (SEM) Partial R2 p-value 
Age -0.50 (0.24) 0.08 0.04 
Gender (Male) 8.1 (5.8) 0.04 0.17 
BMI -0.36 (0.78) 0.00 0.64 
Defect location - 0.09 0.49 
Defect area (log) 0.07 (2.10) 0.00 0.97 
Bone-on-bone (Yes) -10.8 (14.1) 0.00 0.45 
Additional procedure 
(Yes) 
0.79 (5.2) 0.00 0.88 
Patch type (Periosteum) -7.4 (7.5) 0.02 0.33 
Synovial fluid markers  
(baseline levels) 
   HA (log) 
   ADAMTS-4 (log) 
   COMP (log) 
   sCD14 (log) 
 
 
2.1 (3.4) 
-2.0 (1.0) 
1.3 (2.1) 
-1.7 (3.3) 
 
 
0.00 
0.08 
0.01 
0.01 
 
 
0.55 
0.045 
0.53 
0.59 
Plasma markers  
(baseline levels) 
   HA (log) 
   COMP (log) 
 
 
-0.54 (0.58) 
1.3 (3.5) 
 
 
0.02 
0.00 
 
 
0.36 
0.71 
All analyses included the baseline Lysholm score as an independent variable. SEM is 225 
Standard Error of the Mean. The partial R2 is a measure of the correlation of each 226 
variable with the post-op Lysholm score while eliminating the influence of baseline 227 
Lysholm score. 228 
 229 
Table 2B: Multivariable regression analysis of predictors of post-op Lysholm score. 230 
 231 
Component Regression coefficient (SEM) R2 p-value 
Total model 
Baseline Lysholm score 
Age 
ADAMTS-4 level (log) 
 -   
0.74 (0.14) 
-0.49 (0.23) 
-1.95 (0.94) 
0.40 
0.35 
0.08 
0.08 
<0.001 
<0.001 
0.04 
0.04 
SEM is Standard Error of the Mean. The R2 for each separate model component is its 232 
partial R2, the R2 when eliminating the influence of the other components. 233 
 234 
 235 
Regression analyses of predictors of a 10 point improvement in Lysholm score 236 
following ACI treatment (responder analysis).  237 
Amongst our 54 patients, 32 had an improved Lysholm (at least 10 points) after 1 year 238 
and were classed as responders, whereas 22 did not show such an improvement and 239 
were classed as non-responders. Univariable logistic regression analyses found that a 240 
lower age, collagen patch type and lower ADAMTS-4 activity in synovial fluid predicted 241 
a positive response (Table 3A). A multivariable logistic regression model of potential 242 
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predictors demonstrated that age, patch type and ADAMTS-4 levels were again 243 
predictive (Table 3B and Figures 1A-C).  244 
 245 
 Plotting baseline ADAMTS-4 levels versus the change in Lysholm score from 246 
the baseline score suggested that the main predictive aspect of ADAMTS-4 was its 247 
presence rather than its quantity (data not shown). A simple 2-way contingency table 248 
analysis confirmed that this was indeed the case (Table 3C; p=0.05, Fisher’s exact 249 
test). The odds ratio (OR) of 0.33 indicates that when ADAMTS-4 activity was 250 
detectable the odds of being a responder were 3 times smaller than when ADAMTS-4 251 
activity was not detectable. 252 
253 
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Table 3A: Univariable logistic regression analysis of predictors of an increase in 254 
Lysholm score of at least 10 points. 255 
 256 
Variable Odds Ratio 
(SEM) 
C-index 
(concordance) 
p-value 
Baseline Lysholm score 0.98 (0.02) 0.57 0.31 
Age 0.92 (0.03) 0.69 0.01 
Gender (Male) 1.35 (0.82) 0.52 0.75 
BMI 0.94 (0.08) 0.51 0.59 
Defect location - 0.62 1.00 
Defect area (log) 0.90 (0.21) 0.58 0.65 
Bone-on-bone (Yes) 0.00 (0.01) 0.56 0.77 
Additional procedure (Yes) 0.99 (0.56) 0.50 0.98 
Patch type (Periosteum) 0.23 (0.20) 0.58 0.10 
Synovial fluid markers (baseline) 
   HA (log) 
   ADAMTS-4 (log) 
   COMP (log) 
   sCD14 (log) 
 
1.43 (0.54) 
0.82 (0.09) 
0.75 (0.21) 
0.72 (0.29) 
 
0.57 
0.63 
0.61 
0.67 
 
0.34 
0.08 
0.30 
0.42 
Plasma markers (baseline) 
   HA (log) 
   COMP (log) 
 
0.80 (0.27) 
0.92 (0.35) 
 
0.56 
0.52 
 
0.51 
0.83 
SEM is Standard Error of the Mean. 257 
 258 
Table 3B: Multivariable regression analysis of predictors of an increase in Lysholm 259 
score of at least 10 points. 260 
 261 
Component Odds Ratio (SEM) C-index 
(concordance) 
p-value 
Total model 
Age 
Patch type (Periosteum) 
ADAMTS-4 level (log) 
- 
0.91 (0.04) 
0.15 (0.15) 
0.77 (0.10) 
0.78 
 
0.002 
0.01 
0.06 
0.05 
SEM is Standard Error of the Mean. 262 
 263 
Table 3C: Two-way contingency table of the relationship between detectable levels of  264 
ADAMTS-4 and response to ACI treatment. 265 
 266 
Responder Non-detectable ADAMTS-4 Detectable ADAMTS-4 OR p-value 
Yes 23 9 0.33 0.05 
No 10 12   
OR is Odds Ratio. p-value based on Fisher’s exact test. 267 
 268 
Predictors of ADAMTS-4 activity 269 
Finally, using a censored regression model (Table 4), we have found that none of the 270 
demographic or clinical baseline parameters were predictive of ADAMTS-4 activity; 271 
only higher sCD14 levels in synovial fluid were significantly associated with ADAMTS-4 272 
activity level (p=0.003). 273 
274 
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Table 4: Univariable censored regression analysis of predictors of log-transformed 275 
ADAMTS-4 levels. 276 
 277 
Variable Regression coefficient (SEM) p-value 
Concurrent Lysholm 0.01 (0.03) 0.65 
Age 0.01 (0.05) 0.88 
Gender (Male) -0.76 (1.10) 0.49 
BMI -0.04 (0.17) 0.82 
Defect location - 0.90 
Defect area (log) -0.25 (0.39) 0.53 
Bone-on-bone (Yes) 1.03 (2.68) 0.70 
Additional procedure (Yes) 0.48 (1.05) 0.65 
Synovial fluid markers   
   HA (log) 0.58 (0.70) 0.40 
   COMP (log) 0.68 (0.55) 0.21 
   sCD14 (log) 2.73 (1.09) 0.01 
SEM is Standard Error of the Mean. 278 
279 
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Discussion 280 
The over-arching aim of this study was to begin the process of developing a panel of 281 
biomarkers that could help clinicians to successfully treat more patients at an early 282 
stage of joint damage with less invasive treatments and thereby reducing the number 283 
of patients who might otherwise progress to end-stage OA and require knee 284 
replacement10,12. To this end, we have attempted to derive a clinical prediction model 285 
by, performing a series of univariable and multivariable linear and logistic regression 286 
analyses to predict clinical outcome of ACI from biomarker levels and demographic 287 
variables. Important criteria in such models are the precision of regression coefficients 288 
and the ability to perform well over a broad range of samples. The emphasis on 289 
precision implies that hypothesis testing is less relevant, and, as a consequence, no 290 
type I error adjustment was needed despite considering multiple independent 291 
variables40. Ultimately, our model requires validating with a further sample of patients. 292 
The internal validation we performed (see Appendix) is a second-best option, but its 293 
results do suggest that our prediction model will indeed perform well with future 294 
samples. 295 
 When using post-operative Lysholm as the outcome, and including baseline 296 
Lysholm as a covariate, lower age at ACI and lower ADAMTS-4 activity level were 297 
identified as promising predictors of better outcome, and both proved significant in a 298 
multivariable analysis. When an improvement in Lysholm score of at least 10 points 299 
was the definition of an ACI responder, which is an accepted clinical threshold in other 300 
published studies14,34,37, three potential predictors were identified, namely a lower age, 301 
the patch type used in the second stage of the procedure (collagen) and the absence 302 
of ADAMTS-4 activity in synovial fluid. It is not too surprising that age at ACI and patch 303 
type have been identified in these analyses as potential predictors of ACI success in 304 
the clinic. Our group and others have already indicated that age and patch type have 305 
predictive value for ACI in terms of outcome and quality of repair cartilage 306 
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respectively13,17,20,25,31. However, the fact that we have identified ADAMTS-4 activity in 307 
synovial fluid as a potential predictive indicator for ACI is completely novel. It is known 308 
that ADAMTS-4 activity is elevated in the synovial fluid of arthritic joints23,46. Together 309 
with ADAMTS-5 (another member of the ADAMTS gene family), ADAMTS-4 has been 310 
shown to accelerate the loss of aggrecan from cartilage, which is a major contributing 311 
factor in the progression of OA2,35,39. An alternatively spliced variant of the enzyme 312 
(ADAMTS-4_v1), which lacks the spacer domain and to date has only been found to be 313 
produced by osteoarthritic synovium cells, is suggested to contribute similarly to the 314 
loss of aggrecan from the superficial zone of OA cartilage43,44. Elevated ADAMTS-4 315 
activity in the synovial fluid of patients that have a poorer outcome following ACI might 316 
therefore suggest that OA has already progressed too far, meaning that their joints are 317 
less likely to benefit from standard ACI treatment. Interestingly, we have also shown 318 
that none of the patient demographic or injury-associated variables examined in this 319 
study could help to predict ADAMTS-4 activity. Hence, ADAMTS-4 activity is an 320 
independent predictor of post-operative Lysholm score. Previous work that was 321 
conducted on a larger cohort of patients which included a proportion with end-stage 322 
OA33, also investigated the relationship between demographic variables and ADAMTS-323 
4. That study found significantly higher levels of ADAMTS-4 activity in the synovial fluid 324 
of older patients and that ADAMTS-4 activity in synovial fluid correlates with the level of 325 
effusion noted in the knee. The finding of no association with age in the present study 326 
is probably most readily explained by the smaller sample size. When exploring 327 
biomarker associations we have shown that sCD14 levels are directly related to 328 
ADAMTS-4 activity in synovial fluid, this finding is not too surprising as CD14 positive 329 
macrophages are known to drive synovial ADAMTS-4 synthesis as part of the 330 
destructive and inflammatory responses characterised in OA5. 331 
We have endeavoured to include as much patient demographic and injury 332 
information as available in our regression analyses, because it is known that patient 333 
age, sex, BMI and size and location of the defect can impact outcome following ACI4,13 334 
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and may also affect biomarker levels in synovial fluid. However, it was not always 335 
possible to obtain all information for all patients, especially in a retrospective study 336 
such as this. For example, the presence of additional pathologies which are likely to 337 
predispose to ACI failure were not always described at arthroscopy; these might have 338 
included the presence of synovitis, meniscal tears or the state of the subchondral bone. 339 
In addition, since our retrospective sample cohort only had matched data at both 340 
stages from 11 patients, it was not possible to accurately determine the impact of the 341 
Stage I procedure on biomarker levels at Stage II. We acknowledge that this missing 342 
information is a limitation of the study. Whilst studying biomarkers in synovial fluid can 343 
provide more information on the biology of degenerative joint disease than measuring 344 
their levels systemically, the ability to measure levels in blood plasma or serum is much 345 
more practical for widespread use in the clinic.  Alternative methods for detection of 346 
aggrecanase activity have shown promise for correlating levels in synovial fluid and 347 
blood where aggrecan breakdown products are measured as opposed to ADAMTS-4 348 
activity22,23. We aim to evaluate these methodologies for our ACI patient cohort in future 349 
studies using preparations of blood serum and plasma.  350 
To our knowledge, the study of biomarkers in synovial fluids and bloods from 351 
patients treated for cartilage injuries is limited to three published studies27,42,45, only two 352 
of which have analysed biomarkers in conjunction with outcome following ACI 353 
treatment. Nganvongpanit et al monitored serum levels of CS and HA in ten dogs 354 
following ACI and drilling, with levels of CS in serum correlating negatively with quality 355 
of repair27. Vasara et al. followed ten patients pre-ACI to 1 year post-ACI, monitoring 356 
MMP3 and IGF-1, and saw higher levels of these at both time points compared to non-357 
treated controls42. The sample size in our study was larger in comparison, but was still 358 
relatively small (54 patients), which limited the power of our analyses. The coefficient of 359 
determination (R2) between predictor and outcome would need to be at least 0.13 to be 360 
significant at the p=0.05 level, assuming 80% power. This threshold could explain why 361 
our analysis failed to identify demographic variables, such as gender or BMI found to 362 
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be predictive in a previous study which has assessed aspects of cell quality in 363 
predicting the clinical outcome of ACI using slightly more patients (n=80)30.  364 
The high detection limit of two assays (ADAMTS-4 and sCD14) prevented 365 
determining biomarker levels in all patients in our study. When the biomarker is the 366 
independent variable in a regression analysis this poses no problem because a 367 
censored regression analysis can be used33. However, when the biomarker is a 368 
dependent variable another approach is needed. Because sCD14 measurements were 369 
below the detection limit in only one sample, a simple and widely-used imputation 370 
method (LDL/√2) could be used28. However, ADAMTS-4 activity was below the 371 
detection limit in 54/76 samples (71%). With such a large proportion of left-censored 372 
data the simple imputation method would give biased results24,28. Simply omitting all 373 
cases with missing data would be highly inefficient because it discards all information 374 
contained in the left-censored observations24,28. The method we chose (fitting a 375 
censored log-normal distribution to all biomarker values above the detection limit) has 376 
been found to provide unbiased estimates of the regression coefficients in comparative 377 
tests24,28. This method performs best when the ADAMTS-4 data follows a censored log-378 
normal distribution and data from an earlier study in our centre with three times as 379 
many samples above the detection limit found no evidence against the assumption of a 380 
log-normal distribution33. We therefore believe that the statistical methodology we used 381 
to handle the left-censored data below the detection limit conforms to best current 382 
practice. 383 
 In summary, through this report, we have identified that ADAMTS-4 activity in 384 
synovial fluid shows promise as a predictive biomarker to improve ACI patient selection 385 
for cell therapy. We suggest that ADAMTS-4 activity levels in the synovial fluid of joints 386 
with cartilage defects may be used to help identify patients who will have a poorer 387 
outcome following conventional ACI treatment. Specifically, our results and analyses 388 
demonstrate that it is the absence of ADAMTS-4 activity preoperatively in synovial fluid 389 
that has the greatest value in predicting a positive response to ACI. In combination with 390 
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other known predictors of ACI response such as age, gender, BMI and defect 391 
characteristics, the absence of detectable ADAMTS-4 in synovial fluid could be used 392 
when deciding the best treatment for cartilage defect patients. With that information, a 393 
treatment algorithm could be developed containing demographic risk factors and a 394 
panel of biomarker characteristics which will help to inform the preclinical decision. In 395 
addition, ADAMTS-4 activity is in itself a likely therapeutic target for combined 396 
biological treatments. Concurrent administration of molecules that specifically inhibit 397 
aggrecanases8,9 with biological treatments may improve outcomes in patients with high 398 
levels of ADAMTS-4 activity in their joints, who would otherwise be less likely to benefit 399 
from standard ACI treatment.  400 
401 
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